Prime Medicine is powered by groundbreaking technology. As a collective team, we are committed to delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

Developed in the lab of Dr. David R. Liu at the Broad Institute of MIT and Harvard, Prime Editing was published in Nature in December 2019. Prime Editing was immediately recognized as a major technological advance in gene editing, with the potential to overcome key limitations in existing gene editing approaches from addressing most genetic diseases.

Prime Editing galvanized a group of leading academics, company builders, investors and advisors to advance the promising technology for the benefit of patients.

leadership

board of directors

scientific founders

scientific advisory board

our partners


Both Prime Medicine and Beam Therapeutics are separate companies that each emerged from the laboratory of Dr. David R. Liu. Sharing many common interests, Prime and Beam have built a partnership to form a collaborative approach to fighting disease and accelerating the development of Prime Editing to deliver therapies for patients. In the areas of partnership, Prime Medicine and Beam share research, expertise, and intellectual property for assays, know-how, delivery, and manufacturing.